This source provides medical information intended solely for licensed professionals and emphasizes that it is not a substitute for medical advice, diagnosis, or treatment decisions, which remain the responsibility of treating physicians.
January 2026 in “BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY” In this randomized controlled trial, both Botulinum Toxin-A and Triamcinolone Acetonide showed substantial effectiveness in treating patchy Alopecia Areata, but Botulinum Toxin-A avoided complications while Triamcinolone led to skin atrophy in 16.7% of patients.
October 2025 in “Pakistan journal of urology.” This supplementary issue of the Pakistan Journal of Urology contains diverse studies spanning organ donation's significance, surgical techniques, and the comparison of treatments in urology, but it doesn't provide specific research results or detailed findings.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
Personalized care and evidence-based treatments are crucial for managing skin and hair conditions.
This handbook of dermatology provides a comprehensive practical manual for dermatologists, but reports no new research findings.
Tailored nonsurgical cosmetic procedures are crucial for safely treating diverse skin types, especially skin of color.
This study introduced a customizable ELISA for detecting antibodies against botulinum neurotoxin that matches or surpasses other tests in sensitivity and allows for more efficient and animal-friendly testing when combined with the hemidiaphragm assay.
December 2008 in “The American Journal of Cosmetic Surgery” Multi-pass laser skin treatments improved healing, reduced pain, and had no major complications.
This study found that subcutaneous administration of Botulinum toxin type A significantly reduced histamine-induced itch intensity and neurogenic inflammation in human skin compared to saline.
This study found that in mice with alopecia areata, a single subcutaneous injection of botulinum neurotoxin serotype A significantly reduced hair loss and stimulated hair follicle regeneration.
This study found that Botox® was most effective at a 25 U/ml concentration, while Dysport® and Neurobloc® were optimal at 100 U/ml for producing anhidrotic areas after injections.
April 2003 in “Journal of Cutaneous Medicine and Surgery” Lasers are effective for some skin conditions but can cause side effects like scarring and pigment changes; careful selection is important, and botulinum toxin type A is successful in reducing sweat in palmar hyperhidrosis.
June 2026 in “Frontiers in Immunology” This review discusses the role of epithelial–mesenchymal transition in cutaneous fibrotic disorders and highlights potential molecular targets for therapy, but reports no new clinical results.
April 2024 in “Frontiers in pharmacology” This review of Cynoglossum amabile, a traditional Chinese and ethnomedicine, provides insights into its uses, chemical components, biological activities, and toxicity. Highlighting its market potential, the study underscores the importance of indigenous knowledge in drug development despite noted hepatotoxic risk linked to its pyrrolizidine alkaloids.
This study examined the molecular communication in psoriasis cells, highlighting unique immune cell interactions and identifying new features of the hair follicle cell-psoriasis axis. It suggests the potential for targeted therapies at the single-cell level to improve psoriasis treatment.
42 citations
,
January 2014 in “Cold Spring Harbor Perspectives in Medicine” This abstract omits specific findings and does not provide new research results.
32 citations
,
July 2018 in “Scientific Reports” In this study, the authors reported that feeding cashmere goats with essential oil-cobalt significantly enhanced their growth, meat quality, and fiber quality, while stimulating immune-related physiological changes.
2 citations
,
March 2005 in “Cancer biology & therapy” This study found that 95% of untreated advanced-stage follicular lymphoma patients responded to a single course of the Bexxar regimen, with 75% achieving complete remission and remaining disease-free for years.
2 citations
,
July 2007 in “Cancer biology & therapy” This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.
36 citations
,
October 2007 in “Journal of Investigative Dermatology” This study found that overexpression of betacellulin in transgenic mice delayed hair follicle morphogenesis and cycling, increased keratinocyte proliferation, and enhanced wound angiogenesis without affecting wound healing strength.
July 2023 in “International Journal of Molecular Sciences” In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.
This study observed that TBX3 mRNA expression levels were region-specific and correlated with pigmentation patterns in dun Mongolian horses, providing insights into the genetic mechanisms behind their distinctive Bider markings.
3 citations
,
January 2021 in “Molecular genetics & genomic medicine” In this study, novel mutations in the BTD gene were identified in a patient with profound biotinidase deficiency, highlighting the importance of biotinidase activity measurement and mutation analysis for early diagnosis.
January 2026 in “Animals” This study researched the dun coat color in Mongolian horses, finding that variations in TBX3 expression in different skin areas are linked to Bider markings, suggesting TBX3's role in this specific pigment pattern, while further investigation is needed on its regulation.
September 2013 in “Oncology Times” This article discusses the discontinuation of the Bexxar regimen for non-Hodgkin's lymphoma, noting that despite its effectiveness, it was under-prescribed due to marketing and development challenges without reporting new clinical results.
January 1999 in “American Journal of Medical Genetics Part A” This case report describes a rare occurrence of ectodermal dysplasia features in a 14-year-old with MBTPS1 gene variants, expanding the known spectrum of related disorders.
April 2025 in “Revista de Ciências da Saúde Nova Esperança” This review discusses the various therapeutic uses of Botulinum Toxin Type A and reports high levels of patient satisfaction with minimal adverse effects across several conditions, emphasizing its potential therapeutic importance.
34 citations
,
April 1982 in “BMJ”